This is a news story, published by Nature, that relates primarily to N. et al news.
For more N. et al news, you can click here:
more N. et al newsFor more biology news, you can click here:
more biology newsFor more news from Nature, you can click here:
more news from NatureOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
selection gene drives. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug resistance evolution news, genetic resistance news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Programming tumor evolutionNature
•77% Informative
Most targeted anticancer therapies fail due to drug resistance evolution.
Here we show that tumor evolution can be redirected to engineer therapeutic opportunity.
We develop a selection gene drive system that is stably introduced into cancer cells and is composed of two genes, or switches, that couple an inducible fitness advantage with a shared fitness cost.
We show that selection gene drives can eradicate diverse forms of genetic resistance in vitro.
Gene therapy with adenoviral delivery of HSV -tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
Successful gene therapy requires targeting the vast majority of cancer cells.
A synthetic homing endonuclease-based gene drive system in the human malaria mosquito.
J.Jura, N. et al . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer.
VR Score
89
Informative language
96
Neutral language
49
Article tone
formal
Language
English
Language complexity
43
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links